Note: The Cancer Letter has previously published information regarding this and can be found here.
Stephen Meltzer, a professor of medicine and oncology at the Johns Hopkins University School of Medicine, along with a team of researchers, clinicians and biomedical engineers have created a test—the “EsophaCap”—that uses specific genetic biomarkers to detect dangerous changes in the cells that line the inside of the esophagus. The paper was published in Clinical Cancer Research.
AbbVie announced an update on the phase III RESOLVE trial (PCYC-1137) of ibrutinib (Imbruvica) in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents in patients with metastatic pancreatic adenocarcinoma.
Colorectal Cancer Alliance is providing a total of $625,000 in grants to four researchers, including one advancing personalized treatment options for rectal cancer patients and three seeking to understand the root cause of rising colorectal cancer rates in patients under age 50.
The FY19 Defense Appropriation provides $130 million to the Department of Defense Breast Cancer Research Program to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public. FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted […]
Rosanna Morris was named chief operating officer at MD Anderson Cancer Center.
In a letter to the White House and Congressional leaders, 46 health groups urges an end to the government shutdown.
Kyn Therapeutics said it has entered into a global strategic collaboration with Celgene Corp.
Otis W. Brawley was named the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
Last year, FDA approved 19 applications for new cancer drug and biologics as well as 38 supplemental indications and four biosimilars, agency officials said.
